These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 26820797)
1. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. Haagensen EJ; Thomas HD; Mudd C; Tsonou E; Wiggins CM; Maxwell RJ; Moore JD; Newell DR Eur J Cancer; 2016 Mar; 56():69-76. PubMed ID: 26820797 [TBL] [Abstract][Full Text] [Related]
2. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. E J; Xing J; Gong H; He J; Zhang W Tumour Biol; 2015 Feb; 36(2):1091-7. PubMed ID: 25326806 [TBL] [Abstract][Full Text] [Related]
3. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation. Fang DD; Zhang CC; Gu Y; Jani JP; Cao J; Tsaparikos K; Yuan J; Thiel M; Jackson-Fisher A; Zong Q; Lappin PB; Hayashi T; Schwab RB; Wong A; John-Baptiste A; Bagrodia S; Los G; Bender S; Christensen J; Vanarsdale T PLoS One; 2013; 8(6):e67258. PubMed ID: 23826249 [TBL] [Abstract][Full Text] [Related]
4. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063 [TBL] [Abstract][Full Text] [Related]
5. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809 [TBL] [Abstract][Full Text] [Related]
6. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365 [TBL] [Abstract][Full Text] [Related]
7. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487 [TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K signaling pathway in KRAS mutant colon cancer. Hong S; Kim S; Kim HY; Kang M; Jang HH; Lee WS Cancer Med; 2016 Feb; 5(2):248-55. PubMed ID: 26715098 [TBL] [Abstract][Full Text] [Related]
9. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma. Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343 [TBL] [Abstract][Full Text] [Related]
10. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells. Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934 [TBL] [Abstract][Full Text] [Related]
11. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. Garrido-Laguna I; Hong DS; Janku F; Nguyen LM; Falchook GS; Fu S; Wheler JJ; Luthra R; Naing A; Wang X; Kurzrock R PLoS One; 2012; 7(5):e38033. PubMed ID: 22675430 [TBL] [Abstract][Full Text] [Related]
12. Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. Roper J; Sinnamon MJ; Coffee EM; Belmont P; Keung L; Georgeon-Richard L; Wang WV; Faber AC; Yun J; Yilmaz ÖH; Bronson RT; Martin ES; Tsichlis PN; Hung KE Cancer Lett; 2014 Jun; 347(2):204-11. PubMed ID: 24576621 [TBL] [Abstract][Full Text] [Related]
13. Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. Pitts TM; Newton TP; Bradshaw-Pierce EL; Addison R; Arcaroli JJ; Klauck PJ; Bagby SM; Hyatt SL; Purkey A; Tentler JJ; Tan AC; Messersmith WA; Eckhardt SG; Leong S PLoS One; 2014; 9(11):e113037. PubMed ID: 25401499 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727 [TBL] [Abstract][Full Text] [Related]
15. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer. Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139 [TBL] [Abstract][Full Text] [Related]
16. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784 [TBL] [Abstract][Full Text] [Related]
17. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021 [TBL] [Abstract][Full Text] [Related]
18. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154 [TBL] [Abstract][Full Text] [Related]
19. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520 [TBL] [Abstract][Full Text] [Related]
20. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. Temraz S; Mukherji D; Shamseddine A Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]